^
    Back
    Association details:
    Biomarker:STING mutation
    Cancer:Melanoma
    Drug:CS-1018 (STING agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 3317: Discovery of novel STING agonists with robust anti-tumor activity

    Published date:
    05/15/2020
    Excerpt:
    Several lead compounds CS-1018, CS-1020 and CS-1010 activate mouse and human STING variants in vitro with much better potency than natural ligand cGAMP and reference compound X. CS-1018 demonstrated dose dependent robust antitumor activity in B16F10 and MC38 mouse models....We have identified several STING agonists, which demonstrated better cellular potency to mouse and human STING alleles compared to natural ligand cGAMP and reference compound.
    DOI:
    10.1158/1538-7445.AM2020-3317